Nicholas Sosiak CPA, CA’s Post

Going live in 30 minutes with IT'$ YUR $ and our discussion... The ABCs of Part D Drug Plans. #Medicare #MedicareSupplementPlans #medicareadvantageplan #medicareparta #MedicarePartB #MedicarePartD #drugplans https://lnkd.in/g95wPdj

We have just released our Q1 financial results. Find all the key figures and our full statement here: https://lnkd.in/dsWrDgdF #StevanatoGroup #FinancialResults #ManagingComplexityDeliveringValue

What are the price targets NOW for Alpha Tau Medical, NASDAQ-DRTS? The price targets for Alpha Tau Medical (DRTS) stock vary based on analysts’ predictions. Here’s a summary: The consensus rating for DRTS is Buy, based on the current 4 buy ratings from analysts in the last year. The average twelve-month price prediction for Alpha Tau Medical is $12.00. The high price target is $23.00, while the low price target is $8.0012. Keep in mind that these forecasts are subject to change based on market dynamics and company performance. Always consult the most up-to-date information when making investment decisions. 📈🔍 Learn more 1 marketbeat.com2 zacks.com3 wallstreetzen.com4 benzinga.com

Transform your regulatory reporting process, and focus your team on core business needs. Hear from Daniel McCarthy, AlphaCert's Executive General Manager, on how AlphaCert’s Regulatory Reporting solution can automate the preparation of your regulatory reporting data and make direct submissions such as APRA SRS 550 in Australia, and FMA Disclose Register and Quarterly Fund Updates (QFUs) in New Zealand. Find out more about how AlphaCert can streamline your reporting: https://hubs.ly/Q02Fj_XM0

Rightway is here to solve the problems of legacy PBMs https://lnkd.in/eUjXKTk3

🟨 Market Alignment Series: Trending and Spending 🟨 This week we will focus on Eli Lilly The stock had almost doubled since May 2022 and outpaced S&P500 and NASDAQ when the company received FDA approval for Mounjaro (tirzepatide) as an adjunct to diet and exercise for type 2 diabetes. So... here are some bite sized market snapshots: Eli Lilly's valuation stands at $842 billion, 54x projected earnings. Orforglipron could be the first small-molecule weight-loss pill when it launches in 2026, giving Eli Lilly a two-year lead before rivals catch up according to Benzinga.com. A top-10 shareholder of Eli Lilly told the Financial Times that investors are rushing into Eli Lilly, pushing it higher, but it's already priced for perfection. The shareholder warned that investors could face significant risks if concerns arise about competition from the ten other companies with weight-loss drugs or potential pricing pressures. 🟨 My take: Lilly will remain one of the strongest pharma companies in the industry for the foreseeable future. Companies are popping up everywhere to get on the D2C GLP1 train.  New companies like Foundation Health are being stood up to enable health plans to cut out the middleman and take control over pharmacy services, facilitate direct-to-patient experiences for pharmaceutical manufacturers, and allow digital health brands to easily launch innovative, on-brand experiences.  PBM disintermediation is afoot! What are your thoughts on the GLP1 inhibitor market?  Please comment! Fired up to give you weekly updates of what’s going on in the U.S. healthcare markets-your go-to on Friday mornings! It’s my unique viewpoint on where you should place your bets as you make career decisions or determine where to allocate your FTE budgets. Full Branding: Amber Browning-Coyle

Disclosure Under Chapter 9 Section 10 of

Disclosure Under Chapter 9 Section 10 of

Learn all about BMR https://lnkd.in/d4PCre8e

This article will explain some of the issues with SB276: https://lnkd.in/g8yDsxKi